Recent Updates
Recently added Catalysts
IOVA Negative Sentiment Score: 25/100

IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA

Key Takeaway: Iovance Biotherapeutics is facing a class action lawsuit due to alleged failures to disclose significant financial information between May 9, 2024, and May 8, 2025. The lawsuit follows a sharp decline in quarterly revenue, reported at $49.3 million, and a drastic cut in the company's revenue guidance for fiscal year 2025. Following these announcements, Iovance's share price experienced a significant drop of 44.8%. Investors have until July 15, 2025, to file lead plaintiff applications.

Market Sentiment Analysis

CONCERNS & RISKS

  • Iovance executives are charged with failing to disclose material information during the Class Period, potentially affecting investor trust.
  • The company reported a significant revenue decline, with Q1 2025 product revenue dropping from $73.7M to $49.3M.
  • A 40% cut to fiscal year 2025 revenue guidance indicates struggling business performance, revised down from $450M-$475M to $250M-$300M.
  • The share price plummeted 44.8% following the revelation of poor financial results and guidance changes.

Full Press Release Details

NEW ORLEANS, June 11, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Iovance investors should visit us at https://claimsfiler.com/cases/nasdaq-iova/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Iovance and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On May 8, 2025, the Company announced its 1Q 2025 financial results, disclosing a quarterly total product revenue of $49.3M, a significant decline from the prior quarter’s $73.7M, as well as a 40% cut to its full fiscal year 2025 total product revenue guidance from a range of $450M - $475M to $250M - $300M. Further, the Company revealed it was “revising full-year 2025 revenue guidance to reflect recent launch dynamics” of Amtagvi and that “[t]he updated forecast considers experience with ATC [authorized treatment center] growth trajectories and treatment timelines for new ATCs.”
On this news, the price of Iovance’s shares fell 44.8%, from $1.42 per share to close at $1.75 per share on May 9, 2025, on unusually heavy trading volume.
The case is Farberov v. Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file claims against Iovance Biotherapeutics?

Investors must file lead plaintiff applications by July 15, 2025.

What triggered the class action lawsuit against Iovance?

The lawsuit is due to Iovance's failure to disclose crucial information.

When did Iovance announce its 1Q 2025 financial results?

Iovance revealed its 1Q 2025 financial results on May 8, 2025.

How much did Iovance's share price drop after the announcement?

The share price fell 44.8%, from $1.42 to $1.75 per share.

Where can investors find more information on ClaimsFiler?

Investors can visit https://claimsfiler.com/cases/nasdaq-iova/ for details.

Last updated: Jun 12, 2025